Page 25 - Read Online

Lee et al. Vessel Plus 2021;5:8 I http://dx.doi.org/10.20517/2574-1209.2020.72 Page 7 of 8

Future studies leveraging multi-omics promises to increase the dimensionality of pathogenic pathways
linked to AIS, revealing even more novel mechanisms. Moreover, larger studies using more homogeneous
subpopulations of stroke patients will be needed to increase power to detect many more genetic and mutli-
omic associations to provide a more complete understanding of AIS pathogenesis. Thus, stroke translational
research will benefit from fluidity in both forward and reverse directions.

DECLARATIONS
Authors’ contributions
Concepts and writing of this review article: Lee JM, Rosand J, Cruchaga C

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by NIH R01 NS085419, research support from Biogen.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES

1. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis
for the Global Burden of Disease Study 2016. Lancet Neurol 18, 459-480.
2. Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. Bull World Health Organ 2016;94:634-634A.
3. Albers GW, Marks MP, Kemp S, et al; DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion
imaging. N Engl J Med 2018;378:708-18.
4. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of
individual patient data from five randomised trials. Lancet 2016;387:1723-31.
5. Jovin TG, Chamorro A, Cobo E, et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic
stroke. N Engl J Med 2015;372:2296-306.
6. Lee JM, Grabb MC, Zipfel GJ, Choi DW. Brain tissue responses to ischemia. J Clin Invest 2000;106:723-31.
7. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 1999;399:A7-14.
8. Chamorro Á. Neuroprotectants in the Era of Reperfusion Therapy. J Stroke 2018;20:197-207.
9. O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann
Neurol 2006;59:467-77.
10. Degraba TJ, Pettigrew LC. Why do neuroprotective drugs work in animals but not humans? Neurologic Clinics 2000;18:475-93.
11. Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II/III
acute ischemic stroke trials. Stroke 2009;40:577-81.
12. Schmidt-Pogoda A, Bonberg N, Koecke MHM, et al. Why most acute stroke studies are positive in animals but not in patients: a
systematic comparison of preclinical, early phase, and phase 3 clinical trials of neuroprotective agents. Ann Neurol 2020;87:40-51.
13. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008;55:363-89.
14. Grupke S, Hall J, Dobbs M, Bix GJ, Fraser JF. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke:
from review to preview. Clin Neurol Neurosurg 2015;129:1-9.
15. Herson PS, Traystman RJ. Animal models of stroke: translational potential at present and in 2050. Future Neurol 2014;9:541-51.